Elutia Inc.
Elutia Inc. (ELUT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ELUT · as of Jun 9, 2026
Key Statistics
Explore Elutia Inc. Data
elut stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The ELUT analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $8.88, representing +796.79% upside from the current price of $0.99.
Competitors & Peers
elut competitorsELUT
ANVS
BCAB
CALC
CELU
LTRNStock Performance
Full HistoryAbout Elutia Inc.
Elutia Inc. is a commercial-phase biotechnology firm specializing in the creation and market introduction of advanced biologic products designed to deliver therapeutic agents. These innovative solutio…
what is elutia inc. · elut stock overview · elutia inc. company profile · who is elutia inc. ceo · elut NASDAQ · elutia inc. headquarters · elutia inc. business segments
About Stock Overview & Key Data
Elutia Inc. (ELUT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 8, 2020. As of the latest trading session, ELUT stock price is $0.99, with a market capitalization of $43.8M. The stock has returned -47.61% over the past 12 months and +42.95% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Elutia Inc. stock is Buy, with an average 12-month price target of $8.88. In fiscal year 2025, Elutia Inc. reported revenue of $12.3M and net income of $53.4M. For detailed data — including Elutia Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Elutia Inc. (ELUT) stock price is $0.99. The stock is traded on NASDAQ under the ticker symbol ELUT. The 52-week range is $0.50 – $2.64.